AC
CRBP icon

Armistice Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Armistice Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-364,000
Closed -$3.42M – 353
2026
Q1 		$3.42M Sell
364,000
-172,000
-32% -$1.45M 0.06% 138
2025
Q4 		$4.36M Buy
536,000
+344,000
+179% +$4.25M 0.05% 131
2025
Q3 		$2.43M Hold
192,000
– – 0.04% 143
2025
Q2 		$1.32M Sell
192,000
-58,000
-23% -$421K 0.02% 143
2025
Q1 		$1.33M Buy
250,000
+14,000
+6% +$124K 0.02% 156
2024
Q4 		$2.78M Buy
+236,000
New +$3.96M 0.04% 137

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Armistice Capital's CRBP Position: Q2 2026 in Review

Armistice Capital sold out of Corbus Pharmaceuticals (CRBP) in Q2 2026, closing a stake of 364,000 shares — an estimated $3.42M sold.

Armistice Capital first reported a position in CRBP in Q4 2024 and held it in 6 quarters. The position peaked at $4.36M in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Armistice Capital reported no remaining Corbus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Armistice Capital sold 364,000 Corbus Pharmaceuticals shares in Q2 2026, an estimated $3.42M.
  • Armistice Capital first reported a position in Corbus Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Armistice Capital's Corbus Pharmaceuticals position peaked at $4.36M in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.